drugset
drugset / Trial / NCT07212335

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

NCT07212335 ↗

Phase 0 Recruiting 15 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSequentialOpen-labelTreatment

Summary

This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T therapy.

Timeline

Start
2025-10-01
Primary completion
2027-09-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous

Indications

chemotherapy-induced toxicity